Il-17 binding proteins

Abstract

Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

1 - 124 . (canceled) 
     
     
         125 . A method for treating a mammal comprising the step of
 administering to the mammal an effective amount of a composition for the release of a binding protein, wherein the composition comprises:
 (a) a formulation, wherein the formulation comprises a crystallized binding protein, and an ingredient, wherein the binding protein comprises an antigen binding domain capable of binding human IL-17, wherein the antigen binding domain comprises at least one CDR comprising an amino acid sequence selected from the group consisting of: 
   CDR-H1. X 1 -X 2 -X 3 -X 4 -X 5  (SEQ ID NO:925), wherein:
 X 1  is N, A, D, or S; 
 X 2  is Y, F, or L; 
 X 3  is G, D, or A; 
 X 4  is M or I; and 
 X 5  is H, D, or S; 
   CDR-H2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:926), wherein;
 X 1  is V, W, or G; 
 X 2  is I, T, M, or F; 
 X 3  is S, N, T, or D; 
 X 4  is Y or P; 
 X 5  is D, N, or I; 
 X 6  is G, S, L, or E; 
 X 7  is S or G; 
 X 8  is N, T, or E; 
 X 9  is K, T, or A; 
 X 10  is Y, G, N, or V; 
 X 11  is Y or V; 
 X 12  is A; 
 X 13  is D, P, or Q; 
 X 14  is S, K, or N; 
 X 15  is V or F; 
 X 16  is K, R, or Q; and 
 X 17  is G; 
   CDR-H3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:927), wherein;
 X 1  is V, S, E, or I; 
 X 2  is G, S, P, or R; 
 X 3  is A, E, N, or P; 
 X 4  is S, D, or W; 
 X 5  is G, E, F, or L; 
 X 6  is D, G, or W; 
 X 7  is Y, I, N, or G; 
 X 8  is Y, T, G, or A; 
 X 9  is Y or I; 
 X 10  is S, G, or Y; 
 X 11  is Y, F, or T; 
 X 12  is G, T, or is not present; 
 X 13  is L, H, or is not present; 
 X 14  is H or is not present; 
 X 15  is F or is not present; 
 X 16  is D; and 
 X 17  is V, N, or Y; 
   CDR-L1. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13  (SEQ ID NO:928), wherein;
 X 1  is S, R, or K; 
 X 2  is G or A; 
 X 3  is S or D; 
 X 4  is N, K, or Q; 
 X 5  is S or is not present; 
 X 6  is N or is not present; 
 X 7  is I, L, N, or D; 
 X 8  is G or I; 
 X 9  is S, N, G, or D; 
 X 10  is H, R, S, or D; 
 X 11  is S, Y, A, or D; 
 X 12  is V, A, L, or M; and 
 X 13  is N, C, or H; 
   CDR-L2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7  (SEQ ID NO: 929) wherein:
 X 1  is G, Q, Y, or E; 
 X 2  is I, D, or A; 
 X 3  is G, N, S, or T; 
 X 4  is Q, K, or T; 
 X 5  is R, S, or L; 
 X 6  is P, I, or V; and 
 X 7  is S or P; 
 and 
   CDR-L3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11  ID NO:930) wherein:
 X 1  is A, Q, H, or L; 
 X 2  is T or Q; 
 X 3  is W, S, or H; 
 X 4  is D or T; 
 X 5  is D or S; 
 X 6  is S, T, L, or F; 
 X 7  is L, T, or P; 
 X 8  is G, H, or Y; 
 X 9  is G, S, or T; 
 X 10  is Y or is not present; and 
 X 11  is V or is not present; 
   a CDR-H1, a CDR-H2, and a CDR-H3 of any variable heavy region (VH) in Table 21, Table 23, Table 24, or Table 27; and   a CDR-L1, a CDR-L2, and a CDR-L3 of any variable light region (VL) in Table 21, Table 23, Table 25, or Table 27.   (b) at least one polymeric carrier.   
     
     
         126 - 128 . (canceled) 
     
     
         129 . A method for reducing human IL-17 activity comprising contacting human IL-17 with a binding protein such that human IL-17 activity is reduced, wherein the binding protein comprises an antigen binding domain capable of binding human IL-17, wherein the antigen binding domain comprises at least one CDR comprising an amino acid sequence selected from the group consisting of:
 CDR-H1. X 1 -X 2 -X 3 -X 4 -X 5  (SEQ ID NO:925), wherein:
 X 1  is N, A, D, or S; 
 X 2  is Y, F, or L; 
 X 3  is G, D, or A; 
 X 4  is M or I; and 
 X 5  is H, D, or S; 
   CDR-H2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:926), wherein;
 X 1  is V, W, or G; 
 X 2  is I, T, M, or F; 
 X 3  is S, N, T, or D; 
 X 4  is Y or P; 
 X 5  is D, N, or I; 
 X 6  is G, S, L, or E; 
 X 7  is S or G; 
 X 8  is N, T, or E; 
 X 9  is K, T, or A; 
 X 10  is Y, G, N, or V; 
 X 11  is Y or V; 
 X 12  is A; 
 X 13  is D, P, or Q; 
 X 14  is S, K, or N; 
 X 15  is V or F; 
 X 16  is K, R, or Q; and 
 X 17  is G; 
   CDR-H3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:927), wherein;
 X 1  is V, S, E, or I; 
 X 2  is G, S, P, or R; 
 X 3  is A, E, N, or P; 
 X 4  is S, D, or W; 
 X 5  is G, E, F, or L; 
 X 6  is D, G, or W; 
 X 7  is Y, I, N, or G; 
 X 8  is Y, T, G, or A; 
 X 9  is Y or I; 
 X 10  is S, G, or Y; 
 X 11  is Y, F, or T; 
 X 12  is G, T, or is not present; 
 X 13  is L, H, or is not present; 
 X 14  is H or is not present; 
 X 15  is F or is not present; 
 X 16  is D; and 
 X 17  is V, N, or Y; 
   CDR-L1. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13  (SEQ ID NO:928), wherein;
 X 1  is S, R, or K; 
 X 2  is G or A; 
 X 3  is S or D; 
 X 4  is N, K, or Q; 
 X 5  is S or is not present; 
 X 6  is N or is not present; 
 X 7  is I, L, N, or D; 
 X 8  is G or I; 
 X 9  is S, N, G, or D; 
 X 10  is H, R, S, or D; 
 X 11  is S, Y, A, or D; 
 X 12  is V, A, L, or M; and 
 X 13  is N, C, or H; 
   CDR-L2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7  (SEQ ID NO:929) wherein:
 X 1  is G, Q, Y, or E; 
 X 2  is I, D, or A; 
 X 3  is G, N, S, or T; 
 X 4  is Q, K, or T; 
 X 5  is R, S, or L; 
 X 6  is P, I, or V; and 
 X 7  is S or P; 
 and 
   CDR-L3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11  ID NO:930) wherein:
 X 1  is A, Q, H, or L; 
 X 2  is T or Q; 
 X 3  is W, S, or H; 
 X 4  is D or T; 
 X 5  is D or S; 
 X 6  is S, T, L, or F; 
 X 7  is L, T, or P; 
 X 8  is G, H, or Y; 
 X 9  is G, S, or T; 
 X 10  is Y or is not present; and 
 X 11  is V or is not present; 
   a CDR-H1, a CDR-H2, and a CDR-H3 of any variable heavy region (VH) in Table 21, Table 23, Table 24, or Table 27; and   a CDR-L1, a CDR-L2, and a CDR-L3 of any variable light region (VL) in Table 21, Table 23, Table 25, or Table 27.   
     
     
         130 . A method for reducing human IL-17 activity in a human subject suffering from a disorder in which IL-17 activity is detrimental, comprising administering to the human subject a binding protein such that human IL-17 activity in the human subject is reduced, wherein the binding protein comprises an antigen binding domain capable of binding the human IL-17, wherein the antigen binding domain comprises at least one CDR comprising an amino acid sequence selected from the group consisting of:
 CDR-H1. X 1 -X 2 -X 3 -X 4 -X 5  (SEQ ID NO:925), wherein;
 X 1  is N, A, D, or S; 
 X 2  is Y, F, or L; 
 X 3  is G, D, or A; 
 X 4  is M or I; and 
 X 5  is H, D, or S; 
   CDR-H2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:926), wherein;
 X 1  is V, W, or G; 
 X 2  is I, T, M, or F; 
 X 3  is S, N, T, or D; 
 X 4  is Y or P; 
 X 5  is D, N, or I; 
 X 6  is G, S, L, or E; 
 X 7  is S or G; 
 X 8  is N, T, or E; 
 X 9  is K, T, or A; 
 X 10  is Y, G, N, or V; 
 X 11  is Y or V; 
 X 12  is A; 
 X 13  is D, P, or Q; 
 X 14  is S, K, or N; 
 X 15  is V or F; 
 X 16  is K, R, or Q; and 
 X 17  is G; 
   CDR-H3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:927), wherein;
 X 1  is V, S, E, or I; 
 X 2  is G, S, P, or R; 
 X 3  is A, E, N, or P; 
 X 4  is S, D, or W; 
 X 5  is G, E, F, or L; 
 X 6  is D, G, or W; 
 X 7  is Y, I, N, or G; 
 X 8  is Y, T, G, or A; 
 X 9  is Y or I; 
 X 10  is S, G, or Y; 
 X 11  is Y, F, or T; 
 X 12  is G, T, or is not present; 
 X 13  is L, H, or is not present; 
 X 14  is H or is not present; 
 X 15  is F or is not present; 
 X 16  is D; and 
 X 17  is V, N, or Y; 
   CDR-L1. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13  (SEQ ID NO:928), wherein;
 X 1  is S, R, or K; 
 X 2  is G or A; 
 X 3  is S or D; 
 X 4  is N, K, or Q; 
 X 5  is S or is not present; 
 X 6  is N or is not present; 
 X 7  is I, L, N, or D; 
 X 8  is G or I; 
 X 9  is S, N, G, or D; 
 X 10  is H, R, S, or D; 
 X 11  is S, Y, A, or D; 
 X 12  is V, A, L, or M; and 
 X 13  is N, C, or H; 
   CDR-L2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7  (SEQ ID NO: wherein:
 X 1  is G, Q, Y, or E; 
 X 2  is I, D, or A; 
 X 3  is G, N, S, or T; 
 X 4  is Q, K, or T; 
 X 5  is R, S, or L; 
 X 6  is P, I, or V; and 
 X 7  is S or P; 
 and 
   CDR-L3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11  (SEQ ID NO:930), wherein:
 X 1  is A, Q, H, or L; 
 X 2  is T or Q; 
 X 3  is W, S, or H; 
 X 4  is D or T; 
 X 5  is D or S; 
 X 6  is S, T, L, or F; 
 X 7  is L, T, or P; 
 X 8  is G, H, or Y; 
 X 9  is G, S, or T; 
 X 10  is Y or is not present; and 
 X 11  is V or is not present; 
   a CDR-H1, a CDR-H2, and a CDR-H3 of any variable heavy ion in Table 21, Table 23, Table 24, or Table 27; and   a CDR-L1, a CDR-L2, and a CDR-L3 of any variable light region (VL) in Table 21, Table 23, Table 25, or Table 27.   
     
     
         131 . A method for treating a subject for a disease or a disorder in which IL-17 activity is detrimental by administering to the subject a binding protein such that treatment is achieved, wherein the binding protein comprises an antigen binding domain capable of binding the human IL-17, wherein the antigen binding domain comprises at least one CDR comprising an amino acid sequence selected from the group consisting of:
 CDR-H1. X 1 -X 2 -X 3 -X 4 -X 5  (SEQ ID NO:925), wherein;
 X 1  is N, A, D, or S; 
 X 2  is Y, F, or L; 
 X 3  is G, D, or A; 
 X 4  is M or I; and 
 X 5  is H, D, or S; 
   CDR-H2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:926), wherein;
 X 1  is V, W, or G; 
 X 2  is I, T, M, or F; 
 X 3  is S, N, T, or D; 
 X 4  is Y or P; 
 X 5  is D, N, or I; 
 X 6  is G, S, L, or E; 
 X 7  is S or G; 
 X 8  is N, T, or E; 
 X 9  is K, T, or A; 
 X 10  is Y, G, N, or V; 
 X 11  is Y or V; 
 X 12  is A; 
 X 13  is D, P, or Q; 
 X 14  is S, K, or N; 
 X 15  is V or F; 
 X 16  is K, R, or Q; and 
 X 17  is G; 
   CDR-H3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:927), wherein;
 X 1  is V, S, E, or I; 
 X 2  is G, S, P, or R; 
 X 3  is A, E, N, or P; 
 X 4  is S, D, or W; 
 X 5  is G, E, F, or L; 
 X 6  is D, G, or W; 
 X 7  is Y, I, N, or G; 
 X 8  is Y, T, G, or A; 
 X 9  is Y or I; 
 X 10  is S, G, or Y; 
 X 11  is Y, F, or T; 
 X 12  is G, T, or is not present; 
 X 13  is L, H, or is not present; 
 X 14  is H or is not present; 
 X 15  is F or is not present; 
 X 16  is D; and 
 X 17  is V, N, or Y; 
   CDR-L1. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13  (SEQ ID NO:928), wherein;
 X 1  is S, R, or K; 
 X 2  is G or A; 
 X 3  is S or D; 
 X 4  is N, K, or Q; 
 X 5  is S or is not present; 
 X 6  is N or is not present; 
 X 7  is I, L, N, or D; 
 X 8  is G or I; 
 X 9  is S, N, G, or D; 
 X 10  is H, R, S, or D; 
 X 11  is S, Y, A, or D; 
 X 12  is V, A, L, or M; and 
 X 13  is N, C, or H; 
   CDR-L2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7  (SEQ ID NO:929), wherein:
 X 1  is G, Q, Y, or E; 
 X 2  is I, D, or A; 
 X 3  is G, N, S, or T; 
 X 4  is Q, K, or T; 
 X 5  is R, S, or L; 
 X 6  is P, I, or V; and 
 X 7  is S or P; 
 and 
   CDR-L3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11  (SEQ ID NO: 930 ), wherein:
 X 1  is A, Q, H, or L; 
 X 2  is T or Q; 
 X 3  is W, S, or H; 
 X 4  is D or T; 
 X 5  is D or S; 
 X 6  is S, T, L, or F; 
 X 7  is L, T, or P; 
 X 8  is G, H, or Y; 
 X 9  is G, S, or T; 
 X 10  is Y or is not present; and 
 X 11  is V or is not present; 
   a CDR-H1, a CDR-H2, and a CDR-H3 of any variable heavy ion in Table 21, Table 23, Table 24, or Table 27; and   a CDR-L1, a CDR-L2, and a CDR-L3 of any variable light region (VL) in Table 21, Table 23, Table 25, or Table 27.   
     
     
         132 . The method of  claim 131 , wherein the disorder is selected from the group consisting of: rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis  scleroderma , graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein  purpurea , microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic, polyglandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis,  chlamydia, yersinia  and  salmonella  associated arthropathy, spondyloarthropathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease,  pemphigus vulgaris, pemphigus foliaceus , pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis B, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjögren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycaemia, type B insulin resistance with acanthosis  nigricans , hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease NOS, glomerulonephritides, microscopic vasculitis of the kidneys, Lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Sjorgren's syndrome, Takayasu's disease/arteritis, autoimmune thrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liver disease, chronic liver diseases, alcoholic cirrhosis, alcohol-induced liver injury, choleosatatis, idiosyncratic liver disease, Drug-Induced hepatitis, Non-alcoholic Steatohepatitis, allergy and asthma, group B streptococci (GBS) infection, mental disorders (e.g., depression and schizophrenia), Th2 Type and Th1 Type mediated diseases, acute and chronic pain (different forms of pain), and cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma) Abetalipoproteinemia, Acrocyanosis, acute and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute or chronic bacterial infection, acute pancreatitis, acute renal failure, adenocarcinomas, aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-1-antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell degeneration, anti-CD3 therapy, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bundle branch block, Burkitt's lymphoma, Burns, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic leukemia (CML), chronic alcoholism, chronic inflammatory pathologies, chronic lymphocytic leukemia (CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal carcinoma, congestive heart failure, conjunctivitis, contact dermatitis, cor pulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, dermatologic conditions, diabetes, diabetes mellitus, diabetic arteriosclerotic disease, Diffuse Lewy body disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's Syndrome in middle age, drug-induced movement disorders induced by drugs which block CNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis, Epstein-Barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hematophagocytic lymphohistiocytosis, fetal  thymus  implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, fungal sepsis, gas gangrene, gastric ulcer, glomerular nephritis, graft rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, hairy cell leukemia, Hallervorden-Spatz disease, Hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, hepatitis (A), His bundle arrhythmias, HIV infection/HIV neuropathy, Hodgkin's disease, hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hypertension, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic pulmonary fibrosis, antibody mediated cytotoxicity, Asthenia, infantile spinal muscular atrophy, inflammation of the aorta, influenza a, ionizing radiation exposure, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury, ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, kidney transplant rejection,  legionella , leishmaniasis, leprosy, lesions of the corticospinal system, lipedema, liver transplant rejection, lymphedema, malaria, malignant Lymphoma, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, metabolic/idiopathic, migraine headache, mitochondrial multi-system disorder, mixed connective tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations (Mencel Dejerine-Thomas Shi-Drager and Machado-Joseph), myasthenia gravis,  mycobacterium avium intracellulare, mycobacterium tuberculosis , myelodysplastic syndrome, myocardial infarction, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscular atrophies, neutropenic fever, non-Hodgkins lymphoma, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, OKT3® therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures, organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma, paraneoplastic syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic inflammatory disease, perennial rhinitis, pericardial disease, peripheral atherosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia,  pneumocystis carinii  pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiotomy syndrome, preeclampsia, Progressive supranucleo Palsy, primary pulmonary hypertension, radiation therapy, Raynaud's phenomenon and disease, Raynaud's disease, Refsum's disease, regular narrow QRS tachycardia, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, sarcomas,  scleroderma , senile chorea, Senile Dementia of Lewy body type, seronegative arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, solid tumors, specific arrhythmias, spinal ataxia, spinocerebellar degenerations, streptococcal myositis, structural lesions of the cerebellum, Subacute sclerosing panencephalitis, Syncope, syphilis of the cardiovascular system, systemic anaphylaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, T-cell or FAB ALL, Telangiectasia, thromboangitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III hypersensitivity reactions, type IV hypersensitivity, unstable angina, uremia, urosepsis, urticaria, valvular heart diseases, varicose veins, vasculitis, venous diseases, venous thrombosis, ventricular fibrillation, viral and fungal infections, viral encephalitis/aseptic meningitis, viral-associated hemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, acute coronary syndromes, acute idiopathic polyneuritis, acute inflammatory demyelinating polyradiculoneuropathy, acute ischemia, adult Still's disease, alopecia areata, anaphylaxis, anti-phospholipid antibody syndrome, aplastic anemia, arteriosclerosis, atopic eczema, atopic dermatitis, autoimmune dermatitis, autoimmune disorder associated with  streptococcus  infection, autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmune premature ovarian failure, blepharitis, bronchiectasis, bullous pemphigoid, cardiovascular disease, catastrophic antiphospholipid syndrome, celiac disease, cervical spondylosis, chronic ischemia, cicatricial pemphigoid, clinically isolated syndrome (cis) with risk for multiple sclerosis, conjunctivitis, childhood onset psychiatric disorder, chronic obstructive pulmonary disease (COPD), dacryocystitis, dermatomyositis, diabetic retinopathy, diabetes mellitus, disk herniation, disk prolapse, drug induced immune hemolytic anemia, endocarditis, endometriosis, endophthalmitis, episcleritis, erythema multiforme, erythema multiforme major, gestational pemphigoid, Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathic Parkinson's disease, idiopathic interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia, inclusion body myositis, infectious ocular inflammatory disease, inflammatory demyelinating disease, inflammatory heart disease, inflammatory kidney disease, IPF/UIP, iritis, keratitis, keratojunctivitis sicca, Kussmaul disease or Kussmaul-Meier disease, Landry's paralysis, Langerhan's cell histiocytosis, livedo  reticularis , macular degeneration, microscopic polyangiitis, morbus bechterev, motor neuron disorders, mucous membrane pemphigoid, multiple organ failure, myasthenia gravis, myelodysplastic syndrome, myocarditis, nerve root disorders, neuropathy, non-A non-B hepatitis, optic neuritis, osteolysis, ovarian cancer, pauciarticular JRA, peripheral artery occlusive disease (PAOD), peripheral vascular disease (PVD), peripheral artery, disease (PAD), phlebitis, polyarteritis nodosa (or periarteritis nodosa), polychondritis, polymyalgia rheumatica, polio sis, polyarticular JRA, polyendocrine deficiency syndrome, polymyositis, polymyalgia rheumatica (PMR), post-pump syndrome, primary Parkinsonism, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma), prostatitis, pure red cell aplasia, primary adrenal insufficiency, recurrent neuromyelitis optica, restenosis, rheumatic heart disease, sapho (synovitis, acne, pustulosis, hyperostosis, and osteitis),  scleroderma , secondary amyloidosis, shock lung, scleritis, sciatica, secondary adrenal insufficiency, silicone associated connective tissue disease, sneddon-wilkinson dermatosis, spondylitis ankylosans, Stevens-Johnson syndrome (SJS), systemic inflammatory response syndrome, temporal arteritis, toxoplasmic retinitis, toxic epidermal necrolysis, transverse myelitis, TRAPS (tumor necrosis factor receptor, type 1 allergic reaction, type II diabetes, urticaria, usual interstitial pneumonia (UIP), vasculitis, vernal conjunctivitis, viral retinitis, Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular degeneration, wound healing,  yersinia  and  salmonella  associated arthropathy. 
     
     
         133 . A method of treating a patient suffering from a disorder in which IL-17 is detrimental comprising the step of administering a binding protein before, concurrent, or after the administration of a second agent, wherein the binding protein comprises an antigen binding domain capable of binding human the IL-17, wherein the antigen binding domain comprises at least one CDR comprising an amino acid sequence selected from the group consisting of:
 CDR-H1. X 1 -X 2 -X 3 -X 4 -X 5  (SEQ ID NO:925), wherein;
 X 1  is N, A, D, or S; 
 X 2  is Y, F, or L; 
 X 3  is G, D, or A; 
 X 4  is M or I; and 
 X 5  is H, D, or S; 
   CDR-H2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:926), wherein;
 X 1  is V, W, or G; 
 X 2  is I, T, M, or F; 
 X 3  is S, N, T, or D; 
 X 4  is Y or P; 
 X 5  is D, N, or I; 
 X 6  is G, S, L, or E; 
 X 7  is S or G; 
 X 8  is N, T, or E; 
 X 9  is K, T, or A; 
 X 10  is Y, G, N, or V; 
 X 11  is Y or V; 
 X 12  is A; 
 X 13  is D, P, or Q; 
 X 14  is S, K, or N; 
 X 15  is V or F; 
 X 16  is K, R, or Q; and 
 X 17  is G; 
   CDR-H3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17  (SEQ ID NO:927), wherein;
 X 1  is V, S, E, or I; 
 X 2  is G, S, P, or R; 
 X 3  is A, E, N, or P; 
 X 4  is S, D, or W; 
 X 5  is G, E, F, or L; 
 X 6  is D, G, or W; 
 X 7  is Y, I, N, or G; 
 X 8  is Y, T, G, or A; 
 X 9  is Y or I; 
 X 10  is S, G, or Y; 
 X 11  is Y, F, or T; 
 X 12  is G, T, or is not present; 
 X 13  is L, H, or is not present; 
 X 14  is H or is not present; 
 X 15  is F or is not present; 
 X 16  is D; and 
 X 17  is V, N, or Y; 
   CDR-L1. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -X 13  (SEQ ID NO:928), wherein;
 X 1  is S, R, or K; 
 X 2  is G or A; 
 X 3  is S or D; 
 X 4  is N, K, or Q; 
 X 5  is S or is not present; 
 X 6  is N or is not present; 
 X 7  is I, L, N, or D; 
 X 8  is G or I; 
 X 9  is S, N, G, or D; 
 X 10  is H, R, S, or D; 
 X 11  is S, Y, A, or D; 
 X 12  is V, A, L, or M; and 
 X 13  is N, C, or H; 
   CDR-L2. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7  (SEQ ID NO:929), wherein:
 X 1  is G, Q, Y, or E; 
 X 2  is I, D, or A; 
 X 3  is G, N, S, or T; 
 X 4  is Q, K, or T; 
 X 5  is R, S, or L; 
 X 6  is P, I, or V; and 
 X 7  is S or P; 
 and 
   CDR-L3. X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11  (SEQ ID NO:930), wherein:
 X 1  is A, Q, H, or L; 
 X 2  is T or Q; 
 X 3  is W, S, or H; 
 X 4  is D or T; 
 X 5  is D or S; 
 X 6  is S, T, L, or F; 
 X 7  is L, T, or P; 
 X 8  is G, H, or Y; 
 X 9  is G, S, or T; 
 X 10  is Y or is not present; and 
 X 11  is V or is not present; 
   a CDR-H1, a CDR-H2, and a CDR-H3 of any variable heavy region (VH) in Table 21, Table 23, Table 24, or Table 27; and   a CDR-L1, a CDR-L2, and a CDR-L3 of any variable light region (VL) in Table 21, Table 23, Table 25, or Table 27,   
       wherein the second agent is selected from the group consisting of an antibody, or fragment thereof, capable of binding human IL-12; methotrexate; an antibody, or fragment thereof, capable of binding human TNF; corticosteroids, cyclosporin, rapamycin, FK506, and non-steroidal anti-inflammatory agents. 
     
     
         134 - 201 . (canceled)